Multidrug resistant tuberculosis(mdr TB), resistant to at least the two main TB drugs
|
|
|
- Lindsey Oliver
- 7 years ago
- Views:
Transcription
1 Continuing Education Column Extensively Drug Resistant Tuberculosis, XDR TB Jae Seuk Park, MD Department of Internal Medicine, Dankook University College of Medicine E mail: jspark@dankook.ac.kr J Korean Med Assoc 2008; 51(2): Abstract Multidrug resistant tuberculosis(mdr TB), resistant to at least the two main TB drugs isoniazid and rifampicin, has been a threat to TB control because the treatment requires more toxic drugs and longer period with poor treatment outcomes. Recently, more serious concerns have been raised about extensively drug resistant tuberculosis (XDR TB), which shows resistance to fluoroquinolones and aminoglycosides in addition to isoniazid and rifampicin. XDR TB is a serious global health threat because the cure is very difficult as few sensitive anti TB drugs remain. XDR TB develops when first and second line anti TB drugs are misused during the course of treatment, most commonly due to poor compliance of the patients to the treatment regimen. People with XDR TB can pass the XDR TB bacteria to other people. Thus, every effort should be made to prevent the development of XDR TB by establishing an effective TB control program maximizing patient adherence to prescribed anti TB regimen and minimizing contact of XDR TB patients with other people to prevent the spread of XDR TB. Keywords : Tuberculosis; Multidrug resistant; Extensively drug resistant 168
2 Extensively Drug Resistant Tuberculosis 169
3 Park JS Table 1. Number and percentage of XDR TB cases by geographic region and years worldwide, 2000~2004 Geographic Region Industrialized Nations* Total No.(%) No.(%) No.(%) No.(%) No.(%) No.(%) Total no of isolates tested ,499 Total XDR isolates (%) 3(0.5) 2(0.5) 19(4.8) 19(3.7) 25(4.0) 53(2.1) Central and South America Total no of isolates tested Total XDR isolates (%) 5(2.9) 8(4) 5(3.1) 8(4.6) 6(2.1) 32(3.2) Eastern Europe/Western Asia Total no of isolates tested ,153 Total XDR isolates (%) 5(4.8) 9(4.8) 30(4.7) 11(5.0) 0(0) 55(4.8) Africa and Middle East Total no of isolates tested Total XDR isolates (%) 0(0) 0(0) 0(0) 0(0) 1(0.3) 1(0.2) Asia (other than South Korea) Total no of isolates tested Total XDR isolates (%) 0(0) 0(0) 0(0) 2(3.2) 2(1.7) 4(10.2) Total (excluding South Korea) Total no of isolates tested 1, ,366 1,087 1,351 5,751 Total XDR isolates (%) 14(1.4) 19(2.1) 40(2.9) 40(3.7) 34(2.5) 147(2.6) South Korea Total no of isolates tested ,939 11,939 Total XDR isolates (%) (1.7) 200(1.7) * Australia, Belgium, Canada, France, Germany, Ireland, Japan, Portugal, Spain, United Kingdom, United States 170
4 Extensively Drug Resistant Tuberculosis 171
5 Park JS 172
6 Extensively Drug Resistant Tuberculosis 11. Sharma SK, Mohan A. Multidrug resistant tuberculosis: a menace that threatens to destabilize tuberculosis control. Chest 2006; 130: Centers for Disease Control and Prevention. Revised definition of extensively drug resistant tuberculosis. MMWR 2006; 55: Pillay M, Sturm AW. Evolution of the extensively drug resistant F15/LAM4/KZN strain of Mycobacterium tuberculosis in KwaZulu Natal, South Africa. Clin Infect Dis 2007; 45: Helen SC, Stobdan K, Sholpan A, Vinciane S, Zinaida NT, Sabine RG, Hamraev AK, Yared K, Clair M. Multidrug resistant tuberculosis treatment outcomes in Karakalpakstan Uzbekistan: Treatment complexity and XDR TB among treatment failure. PLos One 2007; 2: e Centers for Disease Control and Prevention. Extensively drug resistant tuberculosis United States, MMWR 2007; 56: Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second line drugs worldwide, MMWR 2006; 55: Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Frienland G. Extensively drug resistant tuberculosis as a cause of death in patients co infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368: Singh S, Sankar MM, Gopinath K. High rate of extensively drug resistant tuberculosis in Indian AIDS patients. AIDS 2007; 21: Kim HR, Hwang SS, Kim HJ, Lee SM, Yoo CG, Kim YW, Han SK, Shim YS, Yim JJ. Impact of extensive drug resistance on treatment outcomes in non HIV infected patients with multi drug resistant tuberculosis. Clin Infect Dis 2007; 45: Lee JY, Choi HJ, Lee HY, Joung EY, Huh JW, Oh YM, Lee SD, Kim DS, Kim WD, Shim TS. Recovery rate and characteristics of nontuberculous mycobacterial isolates in a university hospital in Korea. Tuber Respir Dis 2005; 58: Shandil RK, Jayaram R, Kaur P, Gaonkar S, Suresh BL, Ma- 173
7 Park JS hesh BN, Javashree R, Nandi V, Bharath S, Balasubramanian V. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother 2007; 51: Fortun J, Martin Davila P, Navas E, Perez Elias MJ, Cobo J, Tato M, De la Pedrosa EG, Gomez Mampaso E, Moreno S. Linezolid for the treatment of multidrug resistant tuberculosis. J Antimicrob Cehmother 2005; 56: Rubinstein E, Isturiz R, Standiford HC, Smith LG, Oliphant TH, Cammarata S, Hafkin B, Le V, Remington J. Worldwide assessment of linezolid s clinical safety and tolerability: comparator controlled phase III studies. Antimicrob Agents Chemother 2003; 47: O'Brien RJ, Nunn PP. The need for new drugs against tuberculosis: obstacles, opportunities, and next steps. Am J Respir Crit Care Med 2001; 162: Spigelman M, Gillespie S. Tuberculosis drug development pipeline: progress and hope. Lancet 2006; 367: Matteelli A, Migliori GB, Cirillo D, Centis R, Girard E, Raviglilon M. Multidrug resistant and extensively drug resistant Mycobacterium tuberculosis: epidemiology and control. Expert Rev Anti Infect Ther 2007; 5: Kim HJ. Current situation of tuberculosis and its control in Korea. J Korean Med Assoc 2006; 49:
8 Extensively Drug Resistant Tuberculosis Peer Reviewer Commentary 175
Treatment of TB a pharmacy perspective
Treatment of TB a pharmacy perspective Colm McDonald, Antimicrobial Stewardship Pharmacist (Acting) National TB Conference, St. James s Hospital 6 th May 2011 Overview of presentation Role of the pharmacist
Dr Malgosia Grzemska Global TB programme, WHO/HQ Meeting of manufacturers Copenhagen, Denmark, 23-26 November 2015
TB burden and treatment guidelines Dr Malgosia Grzemska Global TB programme, WHO/HQ Meeting of manufacturers Copenhagen, Denmark, 23-26 November 2015 Outline Latest epidemiological data Global programme
Emerging Infectious Disease (4): Drug-Resistant Tuberculosis
S67 Drug-Resistant Tuberculosis Emerging Infectious Disease (4): Drug-Resistant Tuberculosis Chi-Fang You, MD; Han-Ping Ma, MD; Tzong-Luen Wang, MD, PhD; Aming Chor-Min Lin, MD Abstract Before the discovery
Recent Advances in The Treatment of Mycobacterium Tuberculosis
Recent Advances in The Treatment of Mycobacterium Tuberculosis Dr Mohd Arif Mohd Zim Senior Lecturer & Respiratory Physician Faculty of Medicine, Universiti Teknologi MARA mohdarif035@salam.uitm.edu.my
Age In London TB is more common in younger adults aged 15-44 years and peaks in the 25-34 age group (3).
4. TUBERCULOSIS INTRODUCTION Tuberculosis (TB) is an infectious, notifiable disease (meaning there is a requirement by law to report it to government authorities) caused by the bacterium Mycobacterium
Treatment Outcomes and Long-term Survival in Patients with Extensively Drug-resistant Tuberculosis
Treatment Outcomes and Long-term Survival in Patients with Extensively Drug-resistant Tuberculosis Doh Hyung Kim 1, Hee Jin Kim 2, Seung-Kyu Park 3,4, Suck-Jun Kong 5, Young Sam Kim 6, Tae-Hyung Kim 7,
Drug-resistant Tuberculosis
page 1/6 Scientific Facts on Drug-resistant Tuberculosis Source document: WHO (2008) Summary & Details: GreenFacts Context - Tuberculosis (TB) is an infectious disease that affects a growing number of
T tuberculin Skin Test (TST) and QFT-GIT in Military Personnel
2 COMPARISON OF MANTOUX AND QUANTIFERON-TB GOLD TEST FOR DIAGNOSIS OF LATENT TUBERCULOSIS INFECTION IN ARMY PERSONNEL Willeke P.J. Franken 1, Joost F. Timmermans 2, Corine Prins 1, Evert-Jan H.J. Slootman
Challenges in tuberculosis drug research and development
Challenges in tuberculosis drug research and development Ann M Ginsberg & Melvin Spigelman The present decade has seen a reawakening of tuberculosis (TB) drug research and development (R&D), spurred on
Management of Tuberculosis: Indian Guidelines
Chapter 105 Management of Tuberculosis: Indian Guidelines Kuldeep Singh Sachdeva INTRODUCTION Tuberculosis (TB) is an infectious disease caused predominantly by Mycobacterium tuberculosis and among the
TB Prevention, Diagnosis and Treatment. Accelerating advocacy on TB/HIV 15th July, Vienna
TB Prevention, Diagnosis and Treatment Accelerating advocacy on TB/HIV 15th July, Vienna Diagnosis Microscopy of specially stained sputum is the main test for diagnosing TB (1 2 days) TB bacilli seen in
Chapter 1 Overview of Tuberculosis Epidemiology in the United States
Chapter 1 Overview of Tuberculosis Epidemiology in the United States Table of Contents Chapter Objectives.... 1 Progress Toward TB Elimination in the United States.... 3 TB Disease Trends in the United
Treatment. Introduction... 32. Individualized Regimens.. 33. Selection and Dosing of Drugs... 41. Administration of the Regimen...
Treatment 3 Introduction............ 32 Individualized Regimens.. 33 Monoresistance......... 33 Polyresistance.......... 34 Multidrug Resistance..... 35 Extensive Drug Resistance 39 Selection and Dosing
TUBERCULOSIS CONTROL INDIA
TUBERCULOSIS CONTROL INDIA In terms of population coverage, India now has the second largest DOTS (Directly Observed Treatment, Short course) programme in the world. However, India's DOTS programme is
General Information on Tuberculosis
General Information on Tuberculosis ON THE MOVE AGAINST TUBERCULOSIS: Transforming the fi ght towards elimination World TB Day 2011 SAARC Tuberculosis & HIV/AIDS Centre GPO Box No 9517, Kathmandu, Nepal
TB preventive therapy in children. Introduction
TB preventive therapy in children H S Schaaf Department of Paediatrics and Child Health, and Desmond Tutu TB Centre Stellenbosch University, and Tygerberg Children s Hospital Introduction Children are
Positive corporate responses to HIV/AIDS: a snapshot of large cap South African companies
Positive corporate responses to HIV/AIDS: a snapshot of large cap South African companies Introduction The rate of HIV infection continues to grow with 2.7 million new infections recorded globally in 2007.
Tuberculosis and HIV/AIDS Co-Infection: Epidemiology and Public Health Challenges
Tuberculosis and HIV/AIDS Co-Infection: Epidemiology and Public Health Challenges John B. Kaneene, DVM, MPH, PhD University Distinguished Professor of Epidemiology Director, Center for Comparative Epidemiology
MODULE THREE TB Treatment. Treatment Action Group TB/HIV Advocacy Toolkit
MODULE THREE TB Treatment Treatment Action Group TB/HIV Advocacy Toolkit 1 Topics to be covered TB treatment fundamentals Treatment of TB infection and disease TB treatment research Advocacy issues 2 Section
Young-Min Kim. Bachelor in Pharmacology, Seoul National University, South Korea, February 1993
Young-Min Kim Research fellow Environmental Health Center for Atopic Diseases, Samsung Medical Center, 81 Irwon-Ro, Gangnam-Gu, Seoul, Korea Tel: 82-2-3410-3446 Email: ymkim0218@gmail.com Education Ph.D.
Patient Education CONTENTS. Introduction... 12.2
CONTENTS Introduction... 12.2 Purpose... 12.2 General Guidelines... 12.3 Language and Comprehension Barriers... 12.4 Education Topics... 12.5 Medical Diagnosis... 12.5 Contact Investigation... 12.6 Isolation...
Paul E. Lingenfelter President, State Higher Education Executive Officers
Paul E. Lingenfelter President, State Higher Education Executive Officers Western Interstate Commission on Higher Education Monday, November 5, 2007 Forces Flattening the Global Playing Field Fall of Berlin
Guideline. Treatment of tuberculosis in renal disease. Version 3.0
Guideline Treatment of tuberculosis in renal disease Version 3.0 Key critical points Renal failure is recognised as a risk factor for developing tuberculosis. Renal failure is recognised as a risk factor
TB CARE EARLY DETECTION AND PREVENTION OF TUBERCULOSIS (TB) IN CHILDREN. Risk factors in children acquiring TB:
EARLY DETECTION AND PREVENTION OF TUBERCULOSIS (TB) IN CHILDREN Risk factors in children acquiring TB: Children living in the same household as a lung TB patient (especially children under 5) Children
Clinical Scenarios In Childhood TB. Josefina Cadorna Carlos M.D., FPPS, FPIDSP, FSMID Associate Professor of Pediatrics U E R M M M C
Clinical Scenarios In Childhood TB Josefina Cadorna Carlos M.D., FPPS, FPIDSP, FSMID Associate Professor of Pediatrics U E R M M M C Objectives: To present different commonly encountered clinical scenarios
HR Outsourcing Market Forecast: 2012-2016 ~~~
HR Outsourcing Market Forecast: 2012-2016 ~~~ Market Assessment August 2012 About is a specialist BPO analyst company. provides buy-side and sell-side organizations with deeper research and analyses in
Self-Study Modules on Tuberculosis
Self-Study Modules on Tuberculosis Epidemiology of Tuberculosis U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National Center for HIV/AIDS, Viral Hepatitis, STD,
Originally published as:
Originally published as: Reuss, A.M., Wiese-Posselt, M., Weißmann, B., Siedler, A., Zuschneid, I., An Der Heiden, M., Claus, H., Von Kries, R., Haas, W.H. Incidence rate of nontuberculous mycobacterial
TB at Edendale Hospital: Operational Guidelines for Doctors and Nurses. Dr. Michael Clark Medical Officer Edendale Hospital
TB at Edendale Hospital: Operational Guidelines for Doctors and Nurses Dr. Michael Clark Medical Officer Edendale Hospital The Burden What? Tuberculosis (TB) HIV/TB co-infection Drug resistance Where?
Management of a child failing first line TB treatment.
Management of a child failing first line TB treatment. Robert Gie Desmond Tutu Tuberculosis Centre Department of Paediatric and Child Health Stellenbosch University South Africa. Tygerberg Hospital Complex
Objectives. Tuberculosis and Diabetes Challenges and Outcomes 3/23/2015. Global Tuberculosis Epidemiology 2013
Objectives Tuberculosis and Challenges and Outcomes Felicia Dworkin, MD Deputy Director of Medical Affairs Bureau of TB Control New York City Department of Health & Mental Hygiene World TB Day March 15
Massachusetts Department of Public Health Division of Global Populations and Infectious Disease Prevention
Massachusetts Department of Public Health Division of Global Populations and Infectious Disease Prevention Screening Infants and Children for Tuberculosis in Massachusetts Executive Summary In Massachusetts,
Document Management Market Forecast: 2009-2013 ~~~
Document Management Market Forecast: 2009-2013 ~~~ Market Assessment November 2009 DOCUMENT MANAGEMENT MARKET FORECAST: 2009-2013 About is a specialist BPO analyst company. provides buy-side and sell-side
Maximizing Rifamycins
Maximizing Rifamycins Charles A. Peloquin, Pharm.D. Director Infectious Disease Pharmacokinetics Laboratory Professor, College of Pharmacy & The Emerging Pathogens Institute University of Florida Page
Clinical and Laboratory Practices Workshops. Helping to improve laboratory skills and the quality of care in resource-limited settings
Clinical and Laboratory Practices Workshops Helping to improve laboratory skills and the quality of care in resource-limited settings BD is committed to collaborating with governmental and non-governmental
Foreign Taxes Paid and Foreign Source Income INTECH Global Income Managed Volatility Fund
Income INTECH Global Income Managed Volatility Fund Australia 0.0066 0.0375 Austria 0.0045 0.0014 Belgium 0.0461 0.0138 Bermuda 0.0000 0.0059 Canada 0.0919 0.0275 Cayman Islands 0.0000 0.0044 China 0.0000
Tuberculosis OUR MISSION THE OPPORTUNITY
Tuberculosis OUR MISSION Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives. Our Global Health Program is
Outcomes and Use of Therapeutic Drug Monitoring in Multidrug-Resistant Tuberculosis Patients Treated in Virginia, 2009 2014
ORIGINAL ARTICLE http://dx.doi.org/10.4046/trd.2015.78.2.78 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2015;78:78-84 Outcomes and Use of Therapeutic Drug Monitoring in Multidrug-Resistant
Ginny Dowell, RN, BSN October 21, 2015. Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS
Principles of Nurse Case Management Ginny Dowell, RN, BSN October 21, 2015 Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS EXCELLENCE EXPERTISE INNOVATION
Web-based remote monitoring of infant incubators in the ICU
International Journal of Medical Informatics (2003) 71, 151 156 SHORT COMMUNICATION Web-based remote monitoring of infant incubators in the ICU D.I. Shin a, S.J. Huh a, *, T.S. Lee b, I.Y. Kim c a Department
Guideline. Treatment of tuberculosis in pregnant women and newborn infants. Version 3.0
Guideline Treatment of tuberculosis in pregnant women and newborn infants Version 3.0 Key critical points The decision to treat tuberculosis (TB) in pregnancy must consider the potential risks to mother
Borderless Diseases By Sunny Thai
Borderless Diseases By Sunny Thai Millennium Development Goal #6 6. Combat HIV/AIDS, malaria and other borderless diseases. A. Halt and begin reversing spread of HIV by 2015. B. Achieve universal access
Costs of inpatient treatment for multi-drug resistant tuberculosis in South Africa
Costs of inpatient treatment for multi-drug resistant tuberculosis in South Africa Kathryn Schnippel 1, Sydney Rosen 1,2, Kate Shearer 1, Neil Martinson 3,4, Lawrence Long 1, Ian Sanne 1,2, Ebrahim Variava
Role of Quantiferon-TB Gold Assays in Detecting Latent Tuberculous Infection among Contacts of Active Tuberculous Patients *
Med. J. Cairo Univ., Vol. 79, No. 1, June 169-175, 2011 www.medicaljournalofcairouniversity.com Role of Quantiferon-TB Gold Assays in Detecting Latent Tuberculous Infection among Contacts of Active Tuberculous
MANAGEMENT OF DRUG-RESISTANT TUBERCULOSIS POLICY GUIDELINES
MANAGEMENT OF DRUG-RESISTANT TUBERCULOSIS POLICY GUIDELINES 2010 FOREWORD The following policy guidelines are intended for use by health care professionals involved in the complex and difficult task of
TREATING DRUG-SENSITIVE TB IN INDIA: IMPLEMENTATION OF DAILY THERAPY WITH FIXED DOSE COMBINATIONS
TREATING DRUG-SENSITIVE TB IN INDIA: IMPLEMENTATION OF DAILY THERAPY WITH FIXED DOSE COMBINATIONS Policy brief, March 2015 Tuberculosis (TB), a communicable disease that affects 9 million people worldwide,
Screening and preventive therapy for MDR/XDR-TB exposed/infected children (and adults)
Screening and preventive therapy for MDR/XDR-TB exposed/infected children (and adults) H S Schaaf Department of Paediatrics and Child Health, and Desmond Tutu TB Centre Stellenbosch University, and Tygerberg
This is one of a series of flipcharts on these topics : Ante Natal Care, Post Natal Care, Child Health, Child Nutrition, Family Spacing, HIV&AIDS, Tuberculosis, Malaria Tuberculosis About the flipchart
Brochure More information from http://www.researchandmarkets.com/reports/1339929/
Brochure More information from http://www.researchandmarkets.com/reports/1339929/ The 2011 World Forecasts of Machine Tools That Remove Material by Laser or Light, Photon, Ultrasonic, Electro-Discharge,
Victims Compensation Claim Status of All Pending Claims and Claims Decided Within the Last Three Years
Claim#:021914-174 Initials: J.T. Last4SSN: 6996 DOB: 5/3/1970 Crime Date: 4/30/2013 Status: Claim is currently under review. Decision expected within 7 days Claim#:041715-334 Initials: M.S. Last4SSN: 2957
AACSB International Accreditation and Joint Programs
AACSB International Accreditation and Joint Programs Lucienne Mochel Assistant Vice President for Accreditation Services The AACSB Mission To advance quality management education worldwide through accreditation
Supported Payment Methods
Supported Payment Methods Global In the global payments market, credit cards are the most popular payment method. However, BlueSnap expands the payment selection by including not only the major credit
Targeted Testing for Tuberculosis Infection
Targeted Testing for Tuberculosis Infection CONTENTS Introduction... 3.2 Purpose... 3.2 Policy... 3.2 When to Conduct Targeted Testing... 3.3 Approaches to increasing targeted testing and treatment for
FOR NEGLECTED DISEASES
DEVELOPING NEW DRUGS & VACCINES FOR NEGLECTED DISEASES OF THE POOR The Product Developer Landscape March 2012 DEVELOPING NEW DRUGS & VACCINES FOR NEGLECTED DISEASES OF THE POOR The Product Developer Landscape
Accuracy counts! SENSORS WITH ANALOG OUTPUT
Accuracy counts! SENSORS WITH ANALOG OUTPUT OTHER APPLICATIONS: KEY ADVANTAGES: Distance measurement Positioning Profile detection Deformation monitoring Vibration monitoring Process monitoring Detection
41 T Korea, Rep. 52.3. 42 T Netherlands 51.4. 43 T Japan 51.1. 44 E Bulgaria 51.1. 45 T Argentina 50.8. 46 T Czech Republic 50.4. 47 T Greece 50.
Overall Results Climate Change Performance Index 2012 Table 1 Rank Country Score** Partial Score Tendency Trend Level Policy 1* Rank Country Score** Partial Score Tendency Trend Level Policy 21 - Egypt***
Maria Dalbey RN. BSN, MA, MBA March 17 th, 2015
Maria Dalbey RN. BSN, MA, MBA March 17 th, 2015 2 Objectives Participants will be able to : Understand the Pathogenesis of Tuberculosis (TB) Identify the Goals of Public Health for TB Identify Hierarchy
International comparisons of obesity prevalence
International comparisons of obesity prevalence June 2009 International Comparisons of Obesity Prevalence Executive Summary Obesity prevalence among adults and children has been increasing in most developed
CONTROL AND PREVENTION OF ENTERIC FEVER: POLICY AND PRACTICE IN WHO SEARO
CONTROL AND PREVENTION OF ENTERIC FEVER: POLICY AND PRACTICE IN WHO SEARO Professor Lalitha Mendis 8 th International Conference on Typhoid fever And Other Invasive Salmonelloses 1-2 March 2013 WHO Position
Report on Government Information Requests
Report on Government Information January 1 - June 30, 2015 Apple takes our commitment to protecting your data very seriously and we work incredibly hard to deliver the most secure hardware, software and
ecompliance: Revolutionizing Tuberculosis Treatment Designed in collaboration with: Microsoft Research India & Innovators In Health 1
ecompliance: Revolutionizing Tuberculosis Treatment Designed in collaboration with: Microsoft Research India & Innovators In Health 1 Overview Operation ASHA is a non-profit bringing tuberculosis treatment
Supported Payment Methods
Sell Globally in a Snap Supported Payment Methods Global In the global payments market, credit cards are the most popular payment method. However, BlueSnap expands the payment selection by including not
Tuberculosis. TB the disease, its treatment and prevention
Tuberculosis TB the disease, its treatment and prevention Tuberculosis TB (tuberculosis) is an infectious disease that usually affects the lungs, although it can affect any part of the body. About 150
AMBULATORY TREATMENT AND PUBLIC HEALTH MEASURES FOR A PATIENT WITH UNCOMPLICATED PULMONARY TUBERCULOSIS
AMBULATORY TREATMENT AND PUBLIC HEALTH MEASURES FOR A PATIENT WITH UNCOMPLICATED PULMONARY TUBERCULOSIS (UPDATE 2004) Internal guidelines of the Tuberculosis & Chest Service of the Department of Health
Tuberculosis: FAQs. What is the difference between latent TB infection and TB disease?
Tuberculosis: FAQs What is TB disease? Tuberculosis (TB) is a disease caused by bacteria (germs) that are spread from person to person through the air. TB usually affects the lungs, but it can also affect
Increasing Innovation in R&D - Seizing early stage external growth opportunities
Increasing Innovation in R&D - Seizing early stage external growth opportunities Paul R. Eynott, PhD sanofi-aventis, US paul.eynott@sanofi-aventis.com -1- Sommaire -2- CHRISTOPHER A. VIEHBACHER Chief Executive
Make the invisible visible! SENSORS WITH EXCELLENT BACKGROUND SUPPRESSION
Make the invisible visible! SENSORS WITH EXCELLENT BACKGROUND SUPPRESSION photoelectric sensors Thanks to its vision for innovation and technological enhancement, Contrinex keeps on setting new standards
RESEARCH AGENDA ON DRUG RESISTANT TUBERCULOSIS With A Focus On Scaling-up Programmes
RESEARCH AGENDA ON DRUG RESISTANT TUBERCULOSIS With A Focus On Scaling-up Programmes Background The Working Group on MDR-TB is an inter-institutional working group involving institutions/agencies and experts
Targeted Testing and Treatment of Latent Tuberculosis Infection in Adults and Children
C D H S / C T C A J O I N T G U I D E L I N E S Targeted Testing and Treatment of Latent Tuberculosis Infection in Adults and Children Targeted Skin Testing and Treatment of Latent Tuberculosis Infection
Revised National Tuberculosis Control Programme (RNTCP) Dr. NAVPREET
Revised National Tuberculosis Control Programme (RNTCP) Dr. NAVPREET Assistant Prof., Deptt. of Community Medicine GMCH Chandigarh Problem Statement of TB in India India accounts for nearly 1/4 th of global
Pediatric Latent TB Diagnosis and Treatment
Date Updated: April 2015 Guidelines Reviewed: 1. CDC Latent TB Guidelines 2. Harborview Pediatric Clinic Latent TB Management, 2010 3. Pediatric Associates Latent TB Guidelines, 2013 4. Seattle Children
PUBLIC & PRIVATE HEALTH CARE IN CANADA
PUBLIC & PRIVATE HEALTH CARE IN CANADA by Norma Kozhaya, Ph.D. Economist, Montreal Economic Institute before the Canadian Pension & Benefits Institute Winnipeg - June 15, 2007 Possible private contribution
Epidemic and Sporadic Cases of Nontuberculous Mycobacterial Keratitis. Associated With Laser In-Situ Keratomileusis.
Epidemic and Sporadic Cases of Nontuberculous Mycobacterial Keratitis Associated With Laser In-Situ Keratomileusis. Kevin L. Winthrop MD, Ellen B. Steinberg MD, MPH, Gary Holmes MD, Marion A. Kainer MBBS,
Philadelphia TB Newsletter
Philadelphia Department of Public Health Philadelphia TB Newsletter Volume 6, 6, Issue Issue 1 1 WORLD TB DAY EDITION Spring 2012 500 S. Broad Street, 2nd Floor Philadelphia, PA 19146 Michael Nutter Mayor
NON-COMMERCIAL CULTURE AND DRUG-SUSCEPTIBILITY TESTING METHODS FOR SCREENING OF PATIENTS AT RISK OF MULTI-DRUG RESISTANT TUBERCULOSIS
NON-COMMERCIAL CULTURE AND DRUG-SUSCEPTIBILITY TESTING METHODS FOR SCREENING OF PATIENTS AT RISK OF MULTI-DRUG RESISTANT TUBERCULOSIS - POLICY STATEMENT - July 2010 TABLE OF CONTENTS 1. Background... 1
Treating HIV in children with tuberculosis
International AIDS Society - Industry Liaison Forum Meeting 5 March 2012 Treating HIV in children with tuberculosis Helen McIlleron, Division of Clinical Pharmacology University of Cape Town Challenges
T()LED() Name ofpolicy: Mandatory Tuberculosis (TB) Screening of Students from World Health Organization Designated High TB Prevalence Countries
Name ofpolicy: Mandatory Tuberculosis (TB) Screening of Students from World Health Organization Designated High TB Prevalence Countries Policy Number: 3364-81-04-030 T()LED() Revision date: I 0/22/13 Approving
Student Finance and Accessibility in an International Comparative Perspective
Student Finance and Accessibility in an International Comparative Perspective D. Bruce Johnstone Pamela Marcucci International Comparative Higher Education Finance and Accessibility Project 1 The International
No. prev. doc.: 9392/08 SAN 77 DENLEG 48 VETER 5 Subject: EMPLOYMENT, SOCIAL POLICY, HEALTH AND CONSUMER AFFAIRS COUNCIL MEETING ON 9 AND 10 JUNE 2008
COUNCIL OF THE EUROPEAN UNION Brussels, 22 May 2008 9637/08 SAN 88 DENLEG 52 VETER 7 NOTE from: Committee of Permanent Representatives (Part 1) to: Council No. prev. doc.: 9392/08 SAN 77 DENLEG 48 VETER
Effects of Simulation based Training on the Learning Outcome of Nursing Students
, pp.251-255 http://dx.doi.org/10.14257/astl.2015.88.53 Effects of Simulation based Training on the Learning Outcome of Nursing Students Hye-Kyung Oh 1 1 Department of Nursing, Division of Health-Nursing,
Delegation in human resource management
From: Government at a Glance 2009 Access the complete publication at: http://dx.doi.org/10.1787/9789264075061-en Delegation in human resource management Please cite this chapter as: OECD (2009), Delegation
Tuberculosis (TB) Screening Guidelines for Substance Use Disorder Treatment Programs in California
Tuberculosis (TB) Screening Guidelines for Substance Use Disorder Treatment Programs in California 1 of 7 Table of Contents Preface 2 TB Symptoms and TB History 2 Initial Screening 2 Follow-Up Screening
Drug-Resistant Tuberculosis: Old Disease New Threat (April 2013)
The Global Fund Drug-Resistant Tuberculosis: Old Disease New Threat (April 2013) This report was written by the APPG on Global Tuberculosis s Policy Adviser, Simon Logan, in close consultation with the
Report on Government Information Requests
Report on Government Information July 1 - December 31, 2015 Apple takes our commitment to protecting your data very seriously and we work incredibly hard to deliver the most secure hardware, software and
Customer Relationship Management (CRM) Analytics Global Market Analysis - Forecast (2014-2020)
Brochure More information from http://www.researchandmarkets.com/reports/3164949/ Customer Relationship Management (CRM) Analytics Global Market Analysis - Forecast (2014-2020) Description: The report
ANIMAL MODELS FOR THE STUDY OF ANTIMYCOBACTERIAL DRUGS
ANIMAL MODELS FOR THE STUDY OF ANTIMYCOBACTERIAL DRUGS Istituto Superiore di Sanità, Rome Department of Infectious, Parasitic and Immune-mediated Diseases LANFRANCO FATTORINI Villars-sur-Ollon, Switzerland,
How many students study abroad and where do they go?
From: Education at a Glance 2012 Highlights Access the complete publication at: http://dx.doi.org/10.1787/eag_highlights-2012-en How many students study abroad and where do they go? Please cite this chapter
Size and Development of the Shadow Economy of 31 European and 5 other OECD Countries from 2003 to 2015: Different Developments
January 20, 2015 ShadEcEurope31_January2015.doc Size and Development of the Shadow Economy of 31 European and 5 other OECD Countries from 2003 to 2015: Different Developments by Friedrich Schneider *)
Impact of Diabetes on Treatment Outcomes among Maryland Tuberculosis Cases, 2004-2005. Tania Tang PHASE Symposium May 12, 2007
Impact of Diabetes on Treatment Outcomes among Maryland Tuberculosis Cases, 2004-2005 Tania Tang PHASE Symposium May 12, 2007 Presentation Outline Background Research Questions Methods Results Discussion
Brochure More information from http://www.researchandmarkets.com/reports/3278449/
Brochure More information from http://www.researchandmarkets.com/reports/3278449/ The 2016 World Forecasts of Hand-Operated Date, Sealing, or Numbering Stamps; Devices for Printing or Embossing Labels;
MANAGEMENT OF TUBERCULOSIS
MANAGEMENT OF TUBERCULOSIS Dean B. Ellithorpe, M.D. Clinical Professor of Medicine Section of Pulmonary Diseases, Critical Care and Environmental Medicine Tulane University School of Medicine INTRODUCTION
04/2000 11/2002 Institute of Nutritional Sciences, University of Vienna, Austria Doctorate in Nutritional Sciences, Dr. rer. nat.
Curriculum Vitae Dr Katrin Engelhardt, MPH Date of birth 22 July 1974 Nationality German Family status Married (Maiden name: Kreisel), two children Current address: Sydney, Australia Skype engelhardt-php
Managing Contacts. Challenges... 202. General Principles... 204. Summary of Options... 205. Variables to Consider... 205. Treatment Options...
10 Managing Contacts Challenges............ 202 General Principles...... 204 Summary of Options.... 205 Variables to Consider... 205 Treatment Options...... 206 Treatment of Children... 209 Window Prophylaxis....
CNE Progress Chart (CNE Certification Requirements and Test Numbers) (updated 18 October 2000)
Novell Education CNE Progress Chart (CNE Certification Requirements and Test Numbers) (updated 18 October 2000) Prerequisite for all certifications In order to receive a Novell certification the candidate
ACCESS TO AFFORDABLE TREATMENT FOR HIV/AIDS: THE ISSUES
ACCESS TO AFFORDABLE TREATMENT FOR HIV/AIDS: THE ISSUES AIDS Law Unit Legal Assistance Centre July, 2002 INTRODUCTION Although there is currently no cure for HIV/Aids, treatment has, however, been developed
Summary of the risk management plan (RMP) for Sirturo (bedaquiline)
EMA/16634/2014 Summary of the risk management plan (RMP) for Sirturo (bedaquiline) This is a summary of the risk management plan (RMP) for Sirturo, which details the measures to be taken in order to ensure
Tuberculosis And Diabetes. Dr. hanan abuelrus Prof.of internal medicine Assiut University
Tuberculosis And Diabetes Dr. hanan abuelrus Prof.of internal medicine Assiut University TUBERCULOSIS FACTS More than 9 million people fall sick with tuberculosis (TB) every year. Over 1.5 million die
Health Care Reform in Korea: Key Challenges
Health Care Reform in Korea: Key Challenges IMF Conference October 3, 2011 Soonman KWON, Ph.D. Professor of Health Economics & Policy Sh School of fpbli Public Health Seoul National University, South Korea
Chapter 6 Treatment of Tuberculosis Disease
Chapter 6 Treatment of Tuberculosis Disease Table of Contents Chapter Objectives.... 139 Introduction.... 141 Treatment and Monitoring Plan.... 143 Adherence Strategies... 143 TB Disease Treatment Regimens....
Recognised as a world leader and a prominent clinical researcher in South Africa
Expert Talks Prof. Peter Donald Emeritus professor in Pediatrics and Child Health at the Faculty of Health Sciences of the University of Stellenbosch and Tygerberg Children's Hospital, South frica n internationally